NCT05733013 A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
| NCT ID | NCT05733013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-02-07 |
| Primary Completion | 2028-02-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-02-07 with a primary completion date of 2028-02-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years old at time of consent Inclusion Criteria: * Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI. * Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care. * Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration. * Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent. Exclusion Criteria: * RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.
Contact & Investigator
Laura Boucai, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT05733013 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05733013 currently recruiting?
Yes, NCT05733013 is actively recruiting participants. Contact the research team at boucail@mskcc.org for enrollment information.
Where is the NCT05733013 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05733013 clinical trial?
NCT05733013 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Laura Boucai, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.